Rocilinostat (ACY-1215): Selective HDAC6 Inhibitor for Myeloma Research

Executive Summary: Rocilinostat (ACY-1215) is a potent and selective inhibitor of histone deacetylase 6 (HDAC6) with an IC50 of 5 nM, exhibiting minimal activity against other HDAC isoforms (APExBIO product information). In preclinical models, Rocilinostat increases acetylation of α-tubulin, disrupts multiple myeloma (MM) cell viability, and synergizes with proteasome inhibitors to enhance apoptosis (Ibupr summary). Oral administration in MM xenograft mice delays tumor growth and increases survival without notable toxicity. The compound is supplied as a DMSO-soluble, cold-chain reagent for scientific research only.

Biological Rationale

Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that regulates acetylation of non-histone proteins, including α-tubulin. HDAC6 modulates processes such as protein trafficking, cell motility, and stress responses. Overexpression of HDAC6 is associated with cancer cell survival, tumorigenesis, and metastatic potential, particularly in hematological malignancies like multiple myeloma (Sulisobenzonerx article). HDAC6's role in the deacetylation of α-tubulin links it to cytoskeletal dynamics and cellular transport, both crucial in malignant transformation and resistance to therapy. Selective HDAC6 inhibition is thus a targeted strategy to disrupt these cancer-associated pathways while minimizing off-target effects.

Mechanism of Action of Rocilinostat (ACY-1215)

Rocilinostat (ACY-1215) is designed to selectively inhibit HDAC6, with an in vitro IC50 of 5 nM for HDAC6, and negligible activity against HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, and sirtuins 1/2. Slight inhibition of HDAC8 has been reported (product information). The primary biochemical consequence is increased acetylation of α-tubulin, disrupting microtubule function and impairing cancer cell migration and division. This selective inhibition avoids the broad cytotoxicity of pan-HDAC inhibitors, improving safety profiles in preclinical models. In multiple myeloma cells, Rocilinostat impairs DNA synthesis, decreases cell viability, and potentiates apoptosis—especially when combined with proteasome inhibitors such as bortezomib or carfilzomib (Nortriptylinelabs Q&A).

Evidence & Benchmarks

• Rocilinostat (ACY-1215) inhibits HDAC6 with an in vitro IC50 of 5 nM, demonstrating >1,000-fold selectivity over most other HDAC isoforms (APExBIO).
• In multiple myeloma models, Rocilinostat treatment increases acetyl-α-tubulin levels, confirming target engagement (Sulisobenzonerx).
• Alone, Rocilinostat reduces myeloma cell viability and inhibits DNA synthesis in vitro; effects are dose-dependent and enhanced in combination with bortezomib or carfilzomib (Ibupr).
• Oral dosing in MM xenograft mice delays tumor growth and prolongs overall survival without significant toxicity (APExBIO).
• Rocilinostat is soluble in DMSO (≥21.675 mg/mL), but insoluble in water and ethanol, requiring -20°C storage and cold chain shipping (APExBIO).

This article extends the mechanistic scope discussed in Sumoprotease.com by including protocol integration and clarifying DMSO solubility constraints in cell-based assays.

Applications, Limits & Misconceptions

Rocilinostat is used in preclinical research to probe the role of HDAC6 in cancer cell survival, metastasis, and drug resistance. Its selectivity enables the study of HDAC6-driven phenotypes while minimizing off-target HDAC inhibition, which is critical for interpreting epigenetic and cytoskeletal effects. The compound's efficacy in enhancing apoptosis in combination with proteasome inhibitors positions it as a standard for synergistic anti-myeloma research (Ibupr). However, its application is restricted to research use; clinical dosing and safety are not established. The compound should not be used for diagnostic or therapeutic purposes. Long-term solution storage is not recommended due to potential compound degradation.

Common Pitfalls or Misconceptions

• Rocilinostat is not a pan-HDAC inhibitor; it is highly selective for HDAC6, and will not inhibit all deacetylase activity in cells.
• It is not water- or ethanol-soluble; improper solvent use can lead to precipitation and assay variability.
• Results from myeloma models may not extrapolate to solid tumor systems without additional validation.
• Rocilinostat is intended for research only; it is not approved for clinical or diagnostic procedures.
• Do not store diluted solutions long-term; use promptly to avoid degradation (APExBIO).

Workflow Integration & Parameters

• Solvent Preparation: Dissolve Rocilinostat in DMSO to a stock concentration ≥21.675 mg/mL; avoid water and ethanol as solvents (APExBIO).
• Storage Conditions: Store lyophilized compound and DMSO stocks at -20°C; avoid repeated freeze-thaw cycles.
• Working Solution: Prepare fresh working solutions immediately before use; do not store diluted solutions.
• Cell Viability Assays: Typical effective concentrations in MM cell lines range from 0.1 to 10 μM for 24–72 hours, depending on assay endpoints (Nortriptylinelabs).
• Combination Therapy: For synergistic studies, pre-treat cells with Rocilinostat before adding bortezomib or carfilzomib, or use concurrent dosing as per experimental design.

For further assay guidance and troubleshooting, see this technical Q&A, which details cell viability and cytotoxicity protocol optimization for Rocilinostat.

Conclusion & Outlook

Rocilinostat (ACY-1215), supplied by APExBIO, is a highly selective HDAC6 inhibitor that enables precise interrogation of HDAC6-dependent mechanisms in cancer biology. Its robust preclinical efficacy and favorable selectivity profile make it a benchmark tool for multiple myeloma research and for exploring HDAC6's role in cell survival and metastasis. Future research will focus on optimizing combination regimens and expanding the mechanistic understanding of HDAC6 in oncogenic signaling. Broader applications in neural development and primary cilia biology are under investigation, as discussed in Aldosteronemed.com, bridging cancer epigenetics with neurodevelopmental pathways.